The present invention provides a formulation for inhibiting metastasis which includes 150 600 units of IL-2, a nonsteroidal anti-inflammatory drug (NSAID), and cyclophosphamide. The present invention further provides a formulation for inhibiting metastasis that includes IL-1, IL-2, IL-6, IL-8, .delta.-IFN and TNF-.alpha..